iShares S&P GSCI Commodity-Indexed Trust ETF vs Sana Biotechnology Inc — how do they compare? iShares S&P GSCI Commodity-Indexed Trust ETF trades at $36.08 (market cap $1.02B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: iShares S&P GSCI Commodity-Indexed Trust ETF is the larger of the two by market cap, and iShares S&P GSCI Commodity-Indexed Trust ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares S&P GSCI Commodity-Indexed Trust ETF for 40 Days and Sana Biotechnology Inc for 23 Days on average.
| GSG | SANA | |
|---|---|---|
Market Cap | $1.02B | $836.71M |
Volume | 1,256,221 | 4,507,444 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $37.15 | $5.92 |
52-Week Low | $22.45 | $2.68 |
Typical Hold Time | 40 Days | 23 Days |
Enterprise Value | — | $749.96M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →